Biogen (BIIB) revenue and earnings history
Biogen reported revenue of $9.89B for fiscal 2025 (year ended Dec 31, 2025), +2.2% on the year before, and net income of $1.29B.
Over 18 years, from fiscal 2007 to fiscal 2025, revenue grew at a compound rate of +6.5% a year.
Revenue and net income, 19 fiscal years
Annual figures, newest first
| Fiscal year | Revenue | Operating income | Net income | Operating cash flow | Capital expenditure | Free cash flow | Stock-based pay | Share buybacks | Dividends paid | Cash at year end | Total debt at year end | Report |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025ended Dec 31, 2025 | $9.89B+2.2% | — | $1.29B | $2.2B | $154M | $2.05B | $291M | — | — | $3.01B | $6.29B | 10-K |
| 2024ended Dec 31, 2024 |
The latest quarter, insider trades and fund moves: Biogen (BIIB) on OQRO.
Common questions
What was Biogen's revenue in fiscal 2025?
$9.89B for the year ended Dec 31, 2025, as reported in its 10-K filed Feb 6, 2026. That is +2.2% on fiscal 2024 ($9.68B).
How fast has Biogen's revenue grown?
From $3.17B in fiscal 2007 to $9.89B in fiscal 2025: a compound annual growth rate of +6.5% over 18 years. This is arithmetic on the filed figures and says nothing about the years ahead.
Has Biogen been profitable?
Where these figures come from
The SEC’s companyfacts data: every figure Biogen tagged in XBRL in its annual and quarterly reports since 2009 (some reports carry a few earlier years as comparatives). For each fiscal year OQRO keeps the twelve-month totals from the annual report and the cash and debt at year end, and when a later report restates a year, the later figure. Read again whenever the company files.
Figures are as reported, in US dollars, with no adjustment for acquisitions, disposals or one-off items. Earnings per share are left out because a stock split changes them between reports. This page describes the past and is not investment advice. No language model wrote it.
